CORT Stock Overview

The Zacks Medical-Drugs industry is experiencing a high level of innovation. Companies like CORT, AMRX, DYN, NKTR, and CRDL could be valuable options to consider for your investment portfolio.

Corcept (CORT) saw an increase in its share price during the last trading session, with trading volume higher than usual. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.

Corcept (CORT) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #1 (Strong Buy).

Corcept (CORT) has strong growth characteristics that may enable it to significantly exceed market performance.

On January 24, 2025, Kuehn Law, PLLC, a law firm focused on shareholder litigation, is looking into whether some officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) may have violated their responsibilities to shareholders. The investigation is focused on possible self-dealing activities.

Corcept (CORT) has reached its highest point in the last year, but can investors expect further increases? We will examine the company's fundamentals for insights.

Corcept's only medication, Korlym, is used to treat Cushing Syndrome, which is more common than was thought, leading to significant revenue and profit increases. The company is also looking to enter the diabetic market, which could help it grow even further. Their long-term aim is to reach $3 billion in revenue by 2029, mainly through a new drug called Relacorilant that could broaden their market beyond Korlym.

CORT has made advancements in its pipeline by submitting a new drug application for relacorilant, which is intended to help patients with endogenous hypercortisolism.

Corcept Therapeutics Incorporated, based in Redwood City, California, has filed a new drug application with the U.S. Food and Drug Administration. The company focuses on creating treatments for serious health issues by adjusting the effects of cortisol, a hormone. Their new drug, relacorilant, is aimed at helping patients with endogenous hypercortisolis.